Metabolic syndrome and other cardiovascular risk factors are highly prevalent in people with
schizophrenia. Patients are at risk for premature mortality and overall have limited access to …

BackgroundThere is an ongoing debate about the use of atypical antipsychotics as a first-
line treatment for first-episode psychosis. AimsTo examine the evidence base for this …

The lifespan of people with severe mental illness (SMI) is shorter compared to the general
population. This excess mortality is mainly due to physical illness. We report prevalence …

A meta‐analysis was conducted to explore the risk for cardio‐metabolic abnormalities in
drug naïve, first‐episode and multi‐episode patients with schizophrenia and age‐and …

The presence of the metabolic syndrome (MetS) is an important risk factor for cardiovascular
disease and diabetes. There are limited data on the prevalence of MetS in patients with …

Metabolic syndrome (MetS), a constellation of central obesity, hypertension, dyslipidaemia
and glucose intolerance, is highly prevalent in individuals with schizophrenia and conveys …

BACKGROUND: Although the treatment of schizophrenia, arguably one of the most
devastating diseases today, has been immensely helped by the advent of second …

Background Omega-3 fatty acids, in particular, eicosapentaenoic acid (EPA) have been
suggested as augmentation strategies in the treatment of schizophrenia and related …

BackgroundWeight gain is a long-recognized side-effect of antipsychotic (AP) drugs and a
major health concern in the treatment of psychosis. The strength of the causal relationship …

Metabolic syndrome (MetS) has been recognized as a risk factor for cardiovascular
morbidity and mortality in general population and in patients with severe mental illnesses …